Adaptation of the heart to intrinsic and external stress involves complex modifications at the molecular and cellular levels that lead to tissue remodeling, functional and metabolic alterations, and finally to failure depending upon the nature, intensity, and chronicity of the stress. Reactive oxygen species (ROS) have long been considered as merely harmful entities, but their role as second messengers has gradually emerged. At the same time, our comprehension of the multifaceted role of nitric oxide (NO) and the related reactive nitrogen species (RNS) has been upgraded. The tight interlay between ROS and RNS suggests that their imbalance may implicate the impairment in physiological NO/redox-based signaling that contributes to the failing of the cardiovascular system. This review initially provides basic concepts on the role of nitroso/oxidative stress in the pathophysiology of heart failure with a particular focus on sources of ROS/RNS, their downstream targets, and endogenous modulators. Then, the role of NO/redox regulation of cardiomyocyte function, including calcium homeostasis, electrogenesis, and insulin signaling pathways, is described. Finally, an overview of old and emerging therapeutic opportunities in heart failure is presented, focusing on modulation of NO/redox mechanisms and discussing benefits and limitations. Antioxid. Redox Signal. 14, 289–331.
Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study investigators. Lancet, 342:821–828. 1993.
2.
AgoT, KitazonoT, OoboshiH, IyamaT, HanY, TakadaJ, WakisakaM, IbayashiS, UtsumiH, IidaM. Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase. Circulation, 109:227–233. 2004.
3.
AhernG, HsuS, KlyachkoV, JacksonM. Induction of persistent sodium current by exogenous and endogenous nitric oxide. J Biol Chem, 275:28810–28815. 2000.
4.
AhsanM, LekliI, RayD, YodoiJ, DasD. Redox regulation of cell survival by the thioredoxin superfamily: an implication of redox gene therapy in the heart. Antioxid Redox Signal, 11:2741–2758. 2009.
5.
AiX, CurranJ, ShannonT, BersD, PogwizdS. Ca2+/calmodulin-dependent protein kinase modulates cardiac ryanodine receptor phosphorylation and sarcoplasmic reticulum Ca2+ leak in heart failure. Circ Res, 97:1314–1322. 2005.
6.
AikawaR, NagaiT, TanakaM, ZouY, IshiharaT, TakanoH, HasegawaH, AkazawaH, MizukamiM, NagaiR, KomuroI. Reactive oxygen species in mechanical stress-induced cardiac hypertrophy. Biochem Biophys Res Commun, 289:901–907. 2001.
AlfaranoC, SartianiL, NedianiC, MannucciE, MugelliA, CerbaiE, RaimondiL. Functional coupling of angiotensin II type 1 receptor with insulin resistance of energy substrate uptakes in immortalized cardiomyocytes (HL-1 cells)Br J Pharmacol, 153:907–914. 2008.
9.
AllenR, TresiniM. Oxidative stress and gene regulation. Free Rad Biol Med, 28:463–499. 2000.
10.
AltanVM. The pharmacology of diabetic complications. Curr Med Chem, 10:1317–1327. 2003.
11.
AmatoL, PaolissoG, CacciatoreF, FerraraN, FerraraP, CanonicoS, VarricchioM, RengoF. Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group. Diabetes Metab, 23:213–218. 1997.
12.
AmbastaR, KumarP, GriendlingK, SchmidtH, BusseR, BrandesR. Direct interaction of the novel Nox proteins with p22phox is required for the formation of a functionally active NADPH oxidase. J Biol Chem, 279:45935–45941. 2004.
13.
AndreouI, TousoulisD, MiliouA, TentolourisC, ZisimosK, GounariP, SiasosG, PapageorgiouN, PapadimitriouCA, DimopoulosMA, StefanadisC. Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: a randomized placebo-controlled study. Atherosclerosis, 210:194–198. 2010.
14.
AndrewP, MayerB. Enzymatic function of nitric oxide synthases. Cardiovasc Res, 43:521–531. 1999.
15.
AnilkumarN, SirkerA, ShahA. Redox sensitive signaling pathways in cardiac remodeling, hypertrophy and failure. Front Biosci, 14:3168–3187. 2009.
16.
AnkerS, DoehnerW, RauchhausM, SharmaR, FrancisD, KnosallaC, DavosC, CicoiraM, ShamimW, KempM, SegalR, OsterzielK, LeyvaF, HetzerR, PonikowskiP, CoatsA. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation, 107:1991–1997. 2003.
17.
AokiH, IzumoS, SadoshimaJ. Angiotensin II activates RhoA in cardiac myocytes: a critical role of RhoA in angiotensin II-induced premyofibril formation. Circ Res, 82:666–676. 1998.
18.
AshtonE, WindebankE, SkibaM, ReidC, SchneiderH, RosenfeldtF, TonkinA, KrumH. Why did high-dose rosuvastatin not improve cardiac remodeling in chronic heart failure? Mechanistic insights from the UNIVERSE study. Int J Cardiol, 2010.
19.
BakerK, BoozG, DostalD. Cardiac actions of angiotensin II: role of an intracardiac renin- angiotensin system. Annu Rev Physiol, 54:227–241. 1992.
20.
BakkerMK, Kerstjens-FrederikseWS, BuysCH, de WalleHE, dJ-vdBLT. First-trimester use of paroxetine and congenital heart defects: a population-based case-control study. Birth Defects Res A Clin Mol Teratol, 88:94–100. 2010.
21.
BalabanR, NemotoS, FinkelT. Mitochondria, oxidants, and aging. Cell, 120:483–495. 2005.
22.
BallingardJ. b3-adrenoceptor stimulation on top of b1-adrenoceptor blockade. J Mol Cell Cardiol, 17:1539–1542. 2009.
23.
BanK, Noyan-AshrafM, HoeferJ, BolzS, DruckerD, HusainM. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide1 receptor-dependent and -independent pathways. Circulation, 117:2340–2350. 2008.
24.
BannisterJ, BannisterW, RotilioG. Aspect and structure, function, and application of superoxide dismutase. Crit Rev Biochem, 22:111–180. 1987.
25.
BányászT, FülöpL, MagyarJ, SzentandrássyN, VarróA, NP. Endocardial versus epicardial differences in L-type calcium current in canine ventricular myocytes studied by action potential voltage clamp. Cardiovasc Res, 58:66–75. 2003.
26.
BarboneA, HolmesJ, HeerdtP, The’A, NakaY, JoshiN, DainesM, MarksA, OzM, BurkhoffD. Comparison of right and left ventricular responses to left ventricular assist device support in patients with severe heart failure: a primary role of mechanical unloading underlying reverse remodeling. Circulation, 104:670–675. 2001.
27.
BargerP, BrandtJ, LeoneT, WeinheimerC, KellyD. Deactivation of peroxisome proliferator-activated receptor-alfa during cardiachypertrophic growth. J Clin Invest, 105:1723–1730. 2000.
28.
BarlucchiL, LeriA, DostalD, FiordalisoF, TadaH, HintzeT, KajsturaJ, Nadal-GinardB, AnversaP. Canine ventricular myocytes possess a renin-angiotensin system that is upregulated with heart failure. Circ Res, 88:298–304. 2001.
29.
BaumerA, FleschM, WangX, ShenQ, FeuersteinG, BohmM. Antioxidative enzymes in human hearts with idiopathic dilated cardiomyopathy. J Mol Cell Cardiol, 32:121–130. 2000.
30.
BaumgartenCM, ClemoHF. Swelling-activated chloride channels in cardiac physiology and pathophysiology. Prog Biophys Mol Biol, 82:25–42. 2003.
31.
BeckmanJ, KoppenolW. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol, 271:C1424–C1437. 1996.
32.
BedardK, KrauseK. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev, 87:245–313. 2007.
33.
BelAibaR, DjordjevicT, PetryA, DiemerK, BonelloS, BanfiB, HessJ, PogrebniakA, BickelC, GörlachA. NOX5 variants are functionally active in endothelial cells. Free Radic Biol Med, 42:446–459. 2007.
34.
BendallJ, CaveA, HeymesC, GallN, ShahA. Pivotal role of a gp91(phox)- containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation, 105:293–296. 2002.
35.
BendallJ, DamyT, RatajczakP, LoyerX, MonceauV, MartyI, MilliezP, RobidelE, MarotteF, SamuelJ, HeymesC. Role of myocardial neuronal nitric oxide synthase-derived nitric oxide in beta-adrenergic hyporesponsiveness after myocardial infarction-induced heart failure in rat. Circulation, 110:2368–2375. 2004.
36.
BerryC, HareJM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol, 555:589–606. 2004.
37.
BersD. Excitation-Contraction Coupling and Cardiac Contractile Force. 2nd. Dordrecht, The Netherlands: Kluwer Academic, 2001.
38.
BersD, DespaS, BossuytJ. Regulation of Ca2+ and Na+ in normal and failing cardiac myocytes. Ann NY Acad Sci, 1080:165–177. 2006.
39.
BertilssonG, PatroneC, ZachrissonO, AnderssonA, DannaeusK, HeidrichJ, KortesmaaJ, MercerA, NielsenE, RönnholmH, WikströmL. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J Neurosci Res, 86:326–338. 2008.
40.
BertrandL, HormanS, BeauloyeC, VanoverscheldeJL. Insulin signalling in the heart. Cardiovasc Res, 79:238–248. 2008.
41.
BianchiP, PimentelD, MurphyM, ColucciW, PariniA. A new hypertrophic mechanism of serotonin in cardiac myocytes: receptor-independent ROS generation. FASEB J, 19:641–643. 2005.
42.
BitoV, HeinzelF, BiesmansL, AntoonsG, SipidoK. Crosstalk between L-type Ca2+ channels and the sarcoplasmic reticulum: alterations during cardiac remodelling. Cardiovasc Res, 77:315–324. 2008.
43.
BlevinsT, HanJ, NicewarnerD, ChenS, OliveiraJH, AronoffS. Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes. Postgrad Med, 122:118–128. 2010.
44.
BolliR, JeroudiM, PatelB, AruomaO, HalliwellB, LaiE, McCayP. Marked reduction of free radical generation and contractile dysfunction by antioxidant therapy begun at the time of reperfusion. Evidence that myocardial “stunning” is a manifestation of reperfusion injury. Circ Res, 65:607–622. 1989.
45.
BolliR, LiQH, TangXL, GuoY, XuanYT, RokoshG, DawnB. The late phase of preconditioning and its natural clinical application—gene therapy. Heart Fail Rev, 12:189–199. 2007.
46.
BonenA, HanX, HabetsD, FebbraioM, GlatzJ, LuikenJ. A null mutation in skeletal muscle FAT/CD36 reveals its essential role in insulin-and AICAR stimulated fatty acid metabolism. Am J Physiol Endocrinol Metab, 292:E1740–E1174. 2007.
47.
BorchiE, BargelliV, StillitanoF, GiordanoC, SebastianiM, NassiP, d'AmatiG, CerbaiE, NedianiC. Enhanced ROS production by NADPH oxidase is correlated to changes in antioxidant enzyme activity in human heart failure. Biochim Biophys Acta, 1802:331–338. 2010.
48.
BorchiE, ParriM, PapucciL, BecattiM, NassiN, NassiP, NedianiC. Role of NADPH oxidase in H9c2 cardiac muscle cells exposed to simulated ischaemia-reperfusion. J Cell Mol Med, 13:2724–2735. 2009.
49.
BouchéC, SerdyS, KahnC, GoldfineA. The cellular fate of glucose and its relevance in type 2 diabetes. Endocr Rev, 25:807–830. 2004.
50.
BoudinaS, BuggerH, SenaS, O'NeillBT, ZahaVG, IlkunO, WrightJJ, MazumderPK, PalfreymanE, TidwellTJ, TheobaldH, KhalimonchukO, WaymentB, ShengX, RodnickKJ, CentiniR, ChenD, LitwinSE, WeimerBE, AbelED. Contribution of impaired myocardial insulin signaling to mitochondrial dysfunction and oxidative stress in the heart. Circulation, 119:1272–1283. 2009.
51.
BredtD, SnyderS. Isolation of nitric oxide synthatase, a calmodulin-requiring enzyme. Proc Natl Acad Sci USA, 87:682–685. 1990.
52.
BriekeA, DeNofrioD. Right ventricular dysfunction in chronic dilated cardiomyopathy and heart failure. Coron Artery Dis, 16:5–11. 2005.
53.
BrownD, GriendlingK. Nox proteins in signal transduction. Free Rad Biol Med, 47:1239–1253. 2009.
54.
BrownG, BorutaiteV. Nitric oxide and mitochondrial respiration in the heart. Cardiovasc Res, 75:283–290. 2007.
55.
BuchananJ, MazumderP, HuP, ChakrabartiG, RobertsM, YunU, CookseyR, LitwinS, AbelE. Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology, 146:5341–5349. 2005.
56.
BunckMC, DiamantM, CornérA, EliassonB, MalloyJL, ShaginianRM, DengW, KendallDM, TaskinenMR, SmithU, Yki-JärvinenH, HeineRJ. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care, 32:762–768. 2009.
BurkhoffD, WeissR, SchulmanS, Kalil-FilhoR, WannenburgT, GerstenblithG. Influence of metabolic substrate on rat heart function and metabolism at different coronary flows. Am J Physiol Heart Circ Physiol, 261:H741–H750991.
60.
BuseJ, HenryR, HanJ, KimD, FinemanM, BaronA. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care, 27:2628–2635. 2004.
61.
BuseJB, SestiG, SchmidtWE, MontanyaE, ChangCT, XuY, BlondeL, RosenstockJ. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care, 33:1300–1303. 2010.
62.
ByrneJ, GrieveD, BendallJ, LiJ, GoveC, LambethJ, CaveA, ShahA. Contrasting roles of NADPH oxidase isoforms in pressure-overload versus angiotensin II-induced cardiac hypertrophy. Circ Res, 93:802–805. 2003.
63.
ByrneJ, GrieveD, CaveA, ShahA. Oxidative stress and heart failure. Arch Mal Coeur Vaiss, 96:214–221. 2003.
64.
CaldizC, GarciarenaC, DulceR, NovarettoL, YevesA, EnnisI, CingolaniH, Chiappe de CingolaniG, PérezN. Mitochondrial reactive oxygen species activate the slow force response to stretch in felinemyocardium. J Physiol, 584:895–905. 2007.
65.
CampbellD, StamlerJ, StraussH. Redox modulation of L-type calcium channels in ferret ventricular myocytes. Dual mechanism regulation by nitric oxide and S-nitrosothiols. J Gen Physiol, 108:277–293. 1996.
66.
CaoC, LengY, HuangW, LiuX, KufeD. Glutathione peroxidase 1 is regulated by the c-Abl and Arg tyrosine kinases. J Biol Chem, 278:39609–39614. 2003.
67.
CaoC, LengY, KufeD. Catalase activity is regulated by c-Abl and Arg in the oxidative stress response. J Biol Chem, 278:29667–29675. 2003.
68.
CaoC, LengY, LiC, KufeD. Functional interaction between the c-Abl and Arg protein-tyrosine kinases in the oxidative stress response. J Biol Chem, 278:12961–12967. 2003.
69.
CaoC, LengY, LiC, KufeD. Functional interaction between the c-Abl and Arg protein-tyrosine kinases in the oxidative stress response. J Biol Chem, 278:12961–12967. 2003.
70.
CaoC, LengY, LiuX, YiY, LiP, KufeD. Catalase is regulated by ubiquitination and proteosomal degradation. Role of the c-Abl and Arg tyrosine kinases. Biochemistry, 42:10348–10353. 2003.
CasadeiB. The emerging role of neuronal nitric oxide synthase in the regulation of myocardial function. Exp Physiol, 91:943–955. 2006.
73.
CasadeiB, SearsCE. Nitric-oxide-mediated regulation of cardiac contractility and stretch responses. Prog Biophys Mol Biol, 82:67–80. 2003.
74.
CaveAC, BrewerAC, NarayanapanickerA, RayR, GrieveDJ, WalkerS, ShahAM. NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal, 8:691–728. 2006.
75.
CerbaiE, AmbrosioG, PorciattiF, ChiarielloM, GiottiA, MugelliA. Cellular electrophysiological basis for oxygen radical-induced arrhythmias. A patch-clamp study in guinea pig ventricular myocytes. Circulation, 84:1773–1782. 1991.
76.
CerbaiE, CrucittiA, SartianiL, De PaoliP, PinoR, RodriguezML, GensiniG, MugelliA. Long-term treatment of spontaneously hypertensive rats with losartan and electrophysiological remodeling of cardiac myocytes. Cardiovasc Res, 45:388–396. 2000.
77.
ChabowskiA, CoortSL, Calles-EscandonJ, TandonNN, GlatzJF, LuikenJJ, BonenA. The subcellular compartmentation of fatty acid transporters is regulated differently by insulin and by AICAR. FEBS Lett, 579:2428–2432. 2005.
78.
ChabowskiA, GorskiJ, LuikenJJ, GlatzJF, BonenA. Evidence for concerted action of FAT/CD36 and FABPpm to increase plasmalemmal fatty acid transport in the heart. Prostaglandins Leukot Essent Fatty Acids, 77:345–353. 2007.
79.
ChaitmanBR, SkettinoSL, ParkerJO, HanleyP, MeluzinJ, KuchJ, PepineCJ, WangW, NelsonJJ, HebertDA, WolffAA. MARISA Investigators. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol, 43:1375–1382. 2004.
80.
ChanCB, HarperME. Uncoupling proteins: role in insulin resistance and insulin insufficiency. Curr Diabetes Rev, 2:271–283. 2006.
81.
CheongE, TumbevV, AbramsonJ, SalamaG, StoyanovskyDA. Nitroxyl triggers Ca2+ release from skeletal and cardiac sarcoplasmic reticulum by oxidizing ryanodine receptors. Cell Calcium, 37:87–96. 2005.
82.
ChiarugiP, BuricchiF. Protein tyrosine phosphorylation and reversible oxidation: two cross-talking posttranslation modifications. Antioxid Redox Signal, 9:1–24. 2007.
83.
ChillarA, SoSP, RuanCH, ShelatH, GengYJ, RuanKH. Profile of NSAID-targeted arachidonic acid metabolisms in human embryonic stem cells (hESCs): implication of the negative effects of NSAIDs on heart tissue regeneration. Int J Cardiol, 2010[Epub ahead of print].
84.
ChoudharyG, DudleySCJr. Heart failure, oxidative stress, and ion channel modulation. Congest Heart Fail, 8:148–155. 2002.
85.
ClarkeP, GrayA, AdlerA, StevensR, RaikouM, CullC, StrattonI, HolmanR. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes. Diabetologia, 44:298–304. 2001.
86.
CodinaM, ElserJ, MarguliesKB. Current status of stem cell therapy in heart failure. Curr Cardiol Rep, 12:199–208. 2010.
87.
ConstantiniP, ChernyakBV, PetronilliV, BernardiP. Modulation of the mitochondrial permeability transition pore by pyridine nucleotides and dithiol oxidation at two separate sites. J Biol Chem, 271:6746–6751. 1996.
88.
CookSA, MatsuiT, LiL, RosenzweigA. Transcriptional effects of chronic Akt activation in the heart. J Biol Chem, 277:22528–22533. 2002.
89.
CostaADT, GarlidKD. MitoKATP activity in healthy and ischemic hearts. J Bioenerg Biomembr, 41:123–126. 2009.
CuzzocreaS, ZingarelliB, O'ConnorM, SalzmanAL, SzabóC. Effect of L-buthionine-(S,R)-sulphoximine, an inhibitor of gamma-glutamylcysteine synthetase on peroxynitrite- and endotoxic shock-induced vascular failure. Br J Pharmacol, 123:525–553. 1998.
93.
DaiberA. Redox signaling (cross-talk) from and to mitochondria involves mitochondrial pores and reactive oxygen species. Biochim Biophys Acta, 1797:897–906. 2010.
94.
DamyT, RatajczakP, ShahAM, CamorsE, MartyI, HasenfussG, MarotteF, SamuelJL, HeymesC. Increased neuronal nitric oxide synthase-derived NO production in the failing human heart. Lancet, 363:1365–1367. 2004.
95.
DangN, TopkaraV, MercandoM, KayJ, KrugerKH, AboodiMS, OzMC, NakaY. Right heart failure after left ventricular assist device implantation in patients with chronic congestive heart failure. J Heart Lung Transplant, 25:1–6. 2006.
96.
DavisKL, MartinE, TurkoIV, MuradF. Novel effects of nitric oxide. Annu Rev Pharmacol Toxicol, 41:203–236. 2001.
97.
De GiustiVC, CorreaMV, Villa-AbrilleMC, BeltranoC, YevesAM, de CingolaniCE, CingolaniHE, AielloEA. The positive inotropic effect of endothelin-1 is mediated by mitochondrial reactive oxygen species. Life Sci, 83:264–271. 2008.
98.
de HaanJB, BladierC, GriffithsP, KelnerM, O'SheaRD, CheungNS, BronsonRT, SilvestroMJ, WildS, ZhengSS, BeartPM, HertzogPJ, KolaI. Mice with a homozygous null mutation for the most abundant glutathione peroxidase, Gpx1, show increased susceptibility to the oxidative stress-inducing agents paraquat and hydrogen peroxide. J Biol Chem, 273:22528–22536. 1998.
99.
De JongJW, SchoemakerRG, de JongeR, BernocchiP, KeijzerE, HarrisonR, SharmaHS, CeconiC. Enhanced expression and activity of xanthine oxidoreductase in the failing heart. J Mol Cell Cardiol, 32:2083–2089. 2000.
100.
De JongJW, Van der MeerP, NieukoopAS, HuizerT, StroeveRJ, BosE. Xanthine oxidoreductase activity in perfused hearts of various species, including humans. Circ Res, 67:770–773. 1990.
101.
DezfulianC, RaatN, ShivaS, GladwinMT. Role of the anion nitrite in ischemia-reperfusion cytoprotection and therapeutics. Cardiovasc Res, 75:327–338. 2007.
102.
DhallaAK, HillMF, SingalPK. Role of oxidative stress in transition of hypertrophy to heart failure. J Am Coll Cardiol, 28:506–514. 1996.
103.
Di LisaF, BernardiP. Mitochondria and ischemia-reperfusion injury of the heart: fixing a hole. Cardiovasc Res, 70:191–199. 2006.
104.
Di LisaF, BernardiP. Mitochondrial function and myocardial aging. A critical analysis of the role of permeability transition. Cardiovasc Res, 66:222–232. 2005.
105.
DieterichS, BieligkU, BeulichK, HasenfussG, PrestleJ. Gene expression of antioxidant enzymes in the human heart: increased expression of catalase in the end-stage failing heart. Circulation, 101:33–39. 2000.
106.
DikalovSI, DikalovaAE, BikineyevaAT, SchmidtHH, HarrisonDG, GriendlingKK. Distinct roles of Nox1 and Nox4 in basal and angiotensin II stimulated superoxide and hydrogen peroxide production. Free Radic Biol Med, 45:1340–1351. 2008.
107.
DinçerUD, BidaseeKR, GünerS, TayA, OzçelikayAT, AltanVM. The effect of diabetes on expression of beta1-, beta2-, and beta3-adrenoreceptors in rat hearts. Diabetes, 50:455–461. 2001.
108.
DoerriesC, GroteK, Hilfiker-KleinerD, LuchtefeldM, SchaeferA, HollandSM, SorrentinoS, ManesC, SchiefferB, DrexlerH, LandmesserU. Critical role of the NAD(P)H oxidase subunit p47phox for left ventricular remodeling/dysfunction and survival after myocardial infarction. Circ Res, 100:894–903. 2007.
109.
DoyleME, GreigNH, HollowayHW, BetkeyJA, BernierM, EganJM. Insertion of an N-terminal 6-aminohexanoic acid after the 7 amino acid position of glucagon-like peptide-1 produces a longacting hypoglycemic agent. Endocrinology, 142:4462–4468. 2001.
110.
DrexlerH. Endothelium as a therapeutic target in heart failure. Circulation, 98:2652–2655. 1998.
111.
DrogeW. Free radicals in the physiological control of cell function. Physiol Rev, 82:47–95. 2002.
112.
EddyLJ, StewartJR, JonesHP, EngersonTD, McCordJM, DowneyJM. Free radical-producing enzyme, xanthine oxidase, is undetectable in human hearts. Am J Physiol Heart Circ Physiol, 253:H709–H711. 1987.
113.
EdmondsonDE, MatteviA, BindaC, LiM, HubalekF. Structure and mechanism of monoamine oxidase. Curr Med Chem, 11:1983–1993. 2004.
114.
EkelundUE, HarrisonRW, ShokekO, ThakkarRN, TuninRS, SenzakiH, KassDA, MarbanE, HareJM. Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Circ Res, 85:437–445. 1999.
115.
EllmarkSH, DustingGJ, FuiMN, Guzzo-PernellN, DrummondGR. The contribution of Nox4 to NADPH oxidase activity in mouse vascular smooth muscle. Cardiovasc Res, 65:495–504. 2005.
116.
EngberdingN, SpiekermannS, SchaeferA, HeinekeA, WienckeA, MullerM, FuchsM, Hilfiker-KleinerD, HornigB, DrexlerH, LandmesserU. Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug?Circulation, 110:2175–2179. 2004.
117.
EntmanML, BornetEP, van WinkleWB, GoldsteinMA, SchwartzA. Association of glycogenolysis with cardiac sarcoplasmicreticulum. II. Effect of glycogen depletion, deoxycholate solubilizationand cardiac ischemia: evidence for a phorphorylase kinasemembrane complex. J Mol Cell Cardiol, 9:515–528. 1977.
118.
EricksonJR, JoinerML, GuanX, KutschkeW, YangJ, OddisCV, BartlettRK, LoweJS, O'DonnellSE, Ykin-BurnsN, ZimmermanMC, ZimmermanK, HamAJ, WeissRM, SpitzDR, SheaMA, ColbranRJ, MohlerPJ, AndersonME. A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell, 133:462–474. 2008.
119.
EspiraL, CzubrytMP. Emerging concepts in cardiac matrix biology. Can J Physiol Pharmacol, 87:996–1008. 2009.
120.
EvansJ. Antioxidant supplements to prevent or slow down the progression of AMD: a systematic review and meta-analysis. Eye, 22:751–760. 2008.
121.
EvansJL, MadduxBA, GoldifineID. The molecular basis for oxidative stress-induced insulin resistance. Antioxid Redox Signal, 7:1040–1052. 2005.
122.
FangJ, AldermanMH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey. JAMA, 283:2404–2410. 2000.
123.
FengW, LiuG, XiaR, AbramsonJJ, PessahIN. Site-selective modification of hyperreactive cysteines of ryanodine receptor complex by quinones. Mol Pharmacol, 55:821–831. 1999.
124.
FeronO, BelhassenL, KobzikL, SmithTW, KellyRA, MichelT. Endothelial nitric oxide synthase targeting to caveolae. Specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells. J Biol Chem, 271:22810–22814. 1996.
125.
FerreiroCR, ChagasAC, CarvalhoMH, DantasAP, ScavoneC, SouzaLC, BuffoloE, da LuzPL. Expression of inducible nitric oxide synthase is increased in patients with heart failure due to ischemic disease. Braz J Med Biol Res, 37:1313–1320. 2004.
126.
FidzianskaA, BilinskaZT, WalczakE, WitkowskiA, ChojnowskaL. Autophagy in transition from hypertrophic cardiomyopathy to heart failure. J Electron Microsc (Tokyo), 59:181–183. 2010.
127.
FinckBN, HanX, CourtoisM, AimondF, NerbonneJM, KovacsA, GrossRW, KellyDP. A critical role for PPARalphamediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci USA, 100:1226–1231. 2003.
128.
FiordalisoF, LiB, LatiniR, SonnenblickEH, AnversaP, LeriA, KajsturaJ. Myocyte death in streptozotocin-induced diabetes in rats in angiotensin II- dependent. Lab Invest, 80:513–527. 2000.
129.
FischerY, ThomasJ, KampJ, JünglingE, RoseH, Carpéné, KammermeierH. 5-Hydroxytryptamine stimulates glucose transport in cardiomyocytes via a monoamine oxidase-dependent reaction. Biochem J, 311:575–583. 1995.
130.
FlogelU, MerxMW, GodeckeA, DeckingUK, SchraderJ. Myoglobin: a scavenger of bioactive NO. Proc Natl Acad Sci USA, 98:735–740. 2001.
131.
FolkersK, LangsjoenP, WillisR. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci USA, 87:8931–8934. 1990.
132.
FortuñoA, BidegainJ, RobadorP, HermidaJ, López-SagasetaJ, BeloquiO, DíezJ, ZalbaG. Losartan metabolite EXP3179 blocks NADPH oxidase-mediated superoxide production by inhibiting protein kinase C: potential clinical implications in hypertension. Hypertension, 54:744–750. 2009.
133.
FosterDB, Van EykJE, MarbánE, O'RourkeB. Redox signaling and protein phosphorylation in mitochondria: progress and prospects. J Bioenerg Biomembr, 41:159–168. 2009.
134.
GarberA, HenryR, RatnerR, Garcia-HernandezP, Rodriguez-PattziH, Olvera-AlvarezI, HaleP, ZdravkovicM, BodeB. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet, 373:473–481. 2009.
135.
GarlidKD, CostaADT, QuinlanCL, PierreSV, Dos SantosP. Cardioprotective signaling to mitochondria. J Mol Cell Cardiol, 46:858–866. 2009.
136.
GarnierA, FortinD, DelomenieC, MomkenI, VekslerV, Ventura-ClapierR. Depressed mitochondrial transcription factors and oxidative capacity in rat failing cardiac and skeletal muscles. J Physiol, 551:491–501. 2003.
137.
GedulinB, NikoulinaS, SmithP, GedulinG, NielsenL, BaronA, ParkesD, YoungA. Exenatide (exendin-4) improves insulin sensitivity and b-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology, 146:2069–2076. 2005.
138.
GianniniC, LombardoF, CurròF, PomilioM, BucciarelliT, ChiarelliF, MohnA. Effects of high-dose vitamin E supplementation on oxidative stress and microalbuminuria in young adult patients with childhood onset type 1 diabetes mellitus. Diabetes Metab Res Rev, 23:539–546. 2007.
139.
GiassonE, MelocheS. Role of p70 S6 protein kinase in angiotensin IIinduced protein synthesis in vascular smooth muscle cells. J Biol Chem, 270:5225–5231. 1995.
GiuliviC, BoverisA, CadenasE. Hydroxyl radical generation during mitochondrial electron transfer and the formation of 8-hydroxydesoxyguanosine in mitochondrial DNA. Arch Biochem Biophys, 316:909–916. 1995.
GoretskiJ, HollocherT. Trapping of nitric oxide produced during denitrification by extracellular hemoglobin. J Biol Chem, 263:2316–2323. 1988.
144.
GorlachA, BrandesR, NguyenK, AmidiM, DehghaniF, BR. A gp91phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circ Res, 87:26–32. 2000.
145.
GriesdaleDE, de SouzaRJ, van DamRM, HeylandDK, CookDJ, MalhotraA, DhaliwalR, HendersonWR, ChittockDR, FinferS, TalmorD. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. CMAJ, 180:821–827. 2009.
146.
GundewarS, CalvertJW, JhaS, Toedt-PingelI, JiS, NunezD, RamachandranA, Anaya-CisnerosM, TianR, LeferDJ. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res, 104:403–411. 2009.
147.
GupteR, VijayV, MarksB, LevineR, SabbahH, WolinM, RecchiaF, GupteA. Upregulation of glucose-6-phosphate dehydrogenase and NAD(P)H oxidase activity increases oxidative stress in failing human heart. J Card Fail, 13:497–506. 2007.
GuzikT, SadowskiJ, GuzikB, JopekA, KapelakB, PrzybylowskiP, WierzbickiK, KorbutR, HarrisonD, ChannonKM. Coronary artery superoxide production and nox isoform expression in human coronary artery disease. Arterioscler Thromb Vasc Biol, 26:333–339. 2006.
150.
HabetsDD, CoumansWA, El HasnaouiM, ZarrinpashnehE, BertrandL, ViolletB, KiensB, JensenTE, RichterEA, BonenA, GlatzJF, LuikenJJ. Crucial role for LKB1 to AMPKalpha2 axis in the regulation of CD36-mediated long-chain fatty acid uptake into cardiomyocytes. Biochim Biophys Acta, 1791:212–219. 2009.
151.
HaddadF, HuntS, RosenthalD, MurphyD. Right ventricular function in cardiovascular disease: part I. Anatomy, physiology, aging, and functional assessment of the right ventricle. Circulation, 117:1436–1448. 2008.
HareJM, StamlerJS. NO/redox disequilibrium in the failing heart and cardiovascular system. J Clin Invest, 115:509–517. 2005.
156.
HausenloyDJ, MaddockHL, BaxterGF, YellonDM. Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning?Cardiovasc Res, 55:534–543. 2002.
157.
Hendgen-CottaUB, MerxMW, ShivaS, SchmitzJ, BecherS, KlareJP, SteinhoffHJ, GoedeckeA, SchraderJ, GladwinMT, KelmM, RassafT. Nitrite reductase activity of myoglobin regulates respiration and cellular viability in myocardial ischemia-reperfusion injury. Proc Natl Acad Sci USA, 105:10256–10261. 2008.
158.
HeymesC, BendallJ, RatajczakP, CaveA, SamuelJ, HasenfussG, ShahA. Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol, 41:2164–2171. 2003.
159.
HilenskiL, ClempusR, QuinnM, LambethJ, GriendlingK. Distinct subcellular localizations of Nox1 and Nox4 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol, 24:677–683. 2004.
160.
HillF, SingalP. Right and left myocardial antioxidant responses during heart failure subsequent to myocardial infarction. Circulation, 96:2414–2420. 1997.
161.
HillM, SingalP. Antioxidant and oxidative stress changes during heart failure subsequent to myocardial infarction in rats. Am J Pathol, 148:291–300. 1996.
162.
HingtgenS, TianX, YangJ, DunlayS, PeekA, WuY, SharmaR, EngelhardtJ, DavissonR. Nox2-containing NADPH oxidase and Akt activation play a key role in angiotensin II-induced cardiomyocyte hypertrophy. Physiol Genomics, 26:180–191. 2006.
163.
HinkU, DaiberA, KayhanN, TrischlerJ, KraatzC, OelzeM, MollnauH, WenzelP, VahlCF, HoKK, WeinerH, MunzelT. Oxidative inhibition of the mitochondrial aldehyde dehydrogenase promotes nitroglycerin tolerance in human blood vessels. J Am Coll Cardiol, 50:2226–2232. 2007.
164.
HiranandaniN, Bupha-IntrT, JanssenP. SERCA overexpression reduces hydroxyl radical injury in murine myocardium. Am J Physiol Heart Circ Physiol, 291:H3130–H3135. 2006.
165.
HoJK, DuclosRI, HamiltonJA. Interaction of acylcarnitineswith model membranes: a (13)C-NMR study. J Lipid Res, 43:1429–1439. 2002.
166.
HollanderJ, FiebigR, GoreM, OokawaraT, OhnoH, JiL. Superoxide dismutase gene expression is activated by a single bout of exercise in rat skeletal muscle. Pflugers Arch, 442:426–434. 2001.
167.
HolubarschC, RohrbachM, KarraschM, BoehmE, PolonskiL, PonikowskiP, RheinS. A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. Clin Sci (Lond), 113:205–212. 2007.
168.
HoolL. The L-type Ca(2+) channel as a potential mediator of pathology during alterations in cellular redox state. Heart Lung Circ, 18:3–10. 2009.
169.
HoustisN, RosenE, LanderE. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature, 440:944–948. 2006.
170.
HuH, SachsF. Stretch-activated currents in the heart. J Mol Cell Cardiol, 29:1511–1523. 1997.
171.
HuZ, ChenJ, WeiQ, XiaY. Bidirectional actions of hydrogen peroxide on endothelial nitric-oxide synthase phosphorylation and function: co-commitment and interplay of Akt and AMPK. J Bio Chem, 283:25256–25263. 2008.
IdeT, TsutsuiH, KinugawaS, SuematsuN, HayashidaniS, IchikawaK, UtsumiH, MachidaY, EgashiraK, TakeshitaA. Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium. Circ Res, 86:152–157. 2000.
174.
IdeT, TsutsuiH, KinugawaS, UtsumiH, KangD, HattoriN, UchidaK, ArimuraK, EgashiraK, TakeshitaA. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res, 85:357–363. 1999.
175.
IngelssonE, SundstromJ, ArnlovJ, ZetheliusB, LindL. Insulin resistance and risk of congestive heart failure. JAMA, 294:334–341. 2005.
176.
IngwallJ. Energy metabolism in heart failure and remodeling. Cardiovasc Res, 81:412–419. 2009.
177.
IrieH, GaoJ, GaudetteG, CohenI, MathiasR, SaltmanA, KrukenkampI. Both metabolic inhibition and mitochondrial K(ATP) channel opening are myoprotective and initiate a compensatory sarcolemmal outward membrane current. Circulation, 108:341–347. 2003.
178.
JacobsonJ. Statins in endothelial signaling and activation. Antioxid Redox Signal, 11:811–821. 2009.
179.
Janssen-HeiningerY, MossmanB, HeintzN, FormanH, KalyanaramanB, FinkelT, StamlerJ, RheeS, van der VlietA. Redox-based regulation of signal transduction: principles, pitfalls, and promises. Free Radic Biol Med, 45:1–17. 2008.
180.
JanssenM, van der MeerP, De JongJ. Antioxidant defence in rat, pig, guinea pig, and human hearts: comparison with xanthine oxidoreductase activity. Cardiovasc Res, 27:2052–2057. 1993.
JeyarajD, AshwathM, RosenbaumDS. Pathophysiology and clinical implications of cardiac memory. Pacing Clin Electrophysiol, 33:346–352. 2010.
183.
JonesS, GreerJ, van HaperenR, DunckerD, de CromR, LeferD. Endothelial nitric oxide synthase overexpression attenuates congestive heart failure in mice. Proc Natl Acad Sci USA, 100:4891–4896. 2003.
184.
JuY, SaintD, GageP. Hypoxia increases persistent sodium current in rat ventricular myocytes. J Physiol, 497:337–347. 1996.
185.
JurtU, GoriT, RavandiA, BabaeiS, ZemanP, ParkerJD. Differential effects of pentaerythritol tetranitrate and nitroglycerin on the development of tolerance and evidence of lipid peroxidation: a human in vivo study. J Am Coll Cardiol, 38:854–859. 2001.
186.
KahlerA, ZimmermannM, LanghansW. Suppression of hepatic fatty acid oxidation and food intake in men. Nutrition, 15:819–828. 1999.
187.
KaludercicN, TakimotoE, NagayamaT, FengN, LaiE, BedjaD, ChenK, GabrielsonK, BlakelyR, ShihJ, PacakK, KassD, Di LisaF, PaolocciN. Monoamine oxidase A-mediated enhanced catabolism of norepinephrine contributes to adverse remodeling and pump failure in hearts with pressure overload. Circ Res, 106:193–202. 2010.
188.
KampO, MetraM. Nebivolol haemodynamic effects and clinical significance of combined b-blockade and nitric oxide release. Drugs, 70:41–56. 2010.
189.
KanamasaK, HayashiT, KimuraA, IkedaA, IshikawaK. Long-term, continuous treatment with both oral and transdermal nitrates increases cardiac events in healed myocardial infarction patients. Angiology, 53:399–408. 2002.
190.
KanazawaA, NishioY, KashiwagiA, InagakiH, KikkawaR, HoriikeK. Reduced activity of mtTFA decreases the transcription in mitochondria isolated from diabetic rat heart. Am J Physiol Endocrinol Metab, 282:E778–E785. 2002.
191.
KassD, SolaroR. Mechanisms and use of calciumsensitizing agents in the failing heart. Circulation, 113:305–315. 2006.
192.
KatzA. Energetics and the failing heart. Hosp Pract, 26:78–90. 1991.
193.
KatzA. Metabolism of the failing heart. Cardioscience, 4:199–203. 1993.
194.
KatzE, StenbitA, HattonK, DePinhoR, CharronM. Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT4. Nature, 377:151–155. 1995.
195.
KawamuraS, MiyamotoS, BrownJ. Initiation and transduction of stretchinduced RhoA and Rac1 activation through caveolae: cytoskeletal regulation of ERK translocation. J Biol Chem, 278:31111–31117. 2003.
KimuraR, OkouchiM, FujiokaH, IchiyanagiA, RyugeF, MizunoT, ImaedaK, OkayamaN, KamiyaY, AsaiK, JohT. Glucagon-like peptide-1 (GLP-1) protects against methylglyoxal-induced PC12 cell apoptosis through the PI3K/Akt/mTOR/GCLc/redox signaling pathway. Neuroscience, 162:1212–1219. 2009.
198.
KinugawaS, HuangH, WangZ, KaminskiP, WolinM, HintzeT. A defect of neuronal nitric oxide synthase increases xanthine oxidase-derived superoxide anion and attenuates the control of myocardial oxygen consumption by nitric oxide derived from endothelial nitric oxide synthase. Circ Res, 96:355–362. 2005.
199.
KishiK, HayashiH, WangL, KamoharaS, TamaokaK, ShimizuT, UshikubiF, NarumiyaS, EY. Gq-coupled receptors transmit the signal for GLUT4 translocation via an insulin-independent pathway. J Biol Chem, 271:26561–26568. 1996.
200.
KlipA, SchertzerJD, BilanPJ, ThongF, AntonescuC. Regulation of glucose transporter 4 traffic by energy deprivation from mitochondrial compromise. Acta Physiol (Oxf), 196:27–35. 2009.
201.
KlonoffD, BuseJ, NielsenL, GuanX, BowlusC, HolcombeJ, WintleM, MaggsD. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin, 24:275–286. 2008.
202.
KlotzS, BarboneA, ReikenS, HolmesJ, NakaY, OzM, MarksA, BurkhoffD. Left ventricular assist device support normalizes left and right ventricular betaadrenergic pathway properties. J Am Coll Cardiol, 45:668–676. 2005.
203.
KnowlesHJ, TianYM, MoleDR, HarrisAL. Novel mechanism of action for hydralazine: induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases. Circ Res, 95:162–169. 2004.
204.
KobayashiN, HorinakaS, MitaS, YoshidaK, HondaT, KobayashiT, HaraK, NishikimiT, MatsuokaH. Aminoguanidine inhibits mitogen-activated protein kinase and improves cardiac performance and cardiovascular remodeling in failing hearts of salt-sensitive hypertensive rats. J Hypertens, 20:2475–2485. 2002.
205.
KoglerH, FraserH, McCuneS, AltschuldR, MarbanE. Disproportionate enhancement of myocardial contractility by the xanthine oxidase inhibitor oxypurinol in failing rat myocardium. Cardiovasc Res, 59:582–592. 2003.
206.
KonstamMA, NeatonJD, DicksteinK, DrexlerH, KomajdaM, MartinezFA, RieggerGA, MalbecqW, SmithRD, GupthaS, Poole-WilsonPA. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet, 374:1840–1848. 2009.
207.
KovacicS, SoltysC, BarrA, ShiojimaI, WalshK, DyckJ. Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart. J Biol Chem, 278:39422–39427. 2003.
208.
KroonPA, IyerA, ChunduriP, ChanV, BrownL. The cardiovascular nutrapharmacology of resveratrol: pharmacokinetics, molecular mechanisms and therapeutic potential. Curr Med Chem, 17:2424–2455. 2010.
209.
KukidomeD, NishikawaT, SonodaK, ImotoK, FujisawaK, YanoM, MotoshimaH, TaguchiT, MatsumuraT, ArakiE. Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells. Diabetes, 55:120–112. 2006.
210.
LaczaZ, PankotaiE, DWB. Mitochondrial nitric oxide synthase: current concepts and controversies. Front Biosci, 14:4436–4443. 2009.
211.
LambethJ. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol, 4:181–189. 2004.
212.
LandmesserU, DikalovS, PriceS, McCannL, FukaiT, HollandS, MitchW, HarrisonD. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest, 111:1201–1209. 2003.
LehmanJ, BoudinaS, BankeN, SambandamN, HanX, YoungD, LeoneT, GrossR, LewandowskiE, AbelE, KellyD. The transcriptional coactivator PGC-1alpha is essential for maximal and efficient cardiac mitochondrial fatty acid oxidation and lipid homeostasis. Am J Physiol Heart Circ Physiol, 295:H185–H196. 2008.
221.
LeiroJM, AlvarezE, ArranzJA, CanoE, OralloF. Antioxidant activity and inhibitory effects of hydralazine on inducible NOS/COX-2 gene and protein expression in rat peritoneal macrophages. Int Immunopharmacol, 4:163–177. 2004.
222.
LeyvaF, AnkerS, SwanJ, GodslandI, WingroveC, ChuaT, StevensonJ, CoatsA. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J, 18:858–865. 1997.
223.
LiJ, ShahA. Intracellular localization and preassembly of the NADPH oxidase complex in cultured endothelial cells. J Biol Chem, 277:19952–19960. 2002.
224.
LiJ, StouffsM, SerranderL, BanfiB, BettiolE, CharnayY, StegerK, KrauseK, JME. The NADPH oxidase NOX4 drives cardiac differentiation: role in regulating cardiac transcription factors and MAP kinase activation. Mol Biol Cell, 17:3978–3988. 2006.
225.
LiX, LiS, XuZ, LouM, AndingP, LiuD, RoyS, RozanskiG. Redox control of K+ channel remodeling in rat ventricle. J Mol Cell Cardiol, 40:339–349. 2006.
226.
LiY, ChenD, WatkinsS, FeldmanA. Mitochondrial abnormalities in tumor necrosis factor-alpha-induced heart failure are associated with impaired DNA repair activity. Circulation, 104:2492–2497. 2001.
227.
LijnenP, PetrovV. Renin-angiotensin system, hypertrophy and gene expression in cardiac myocytes. J Mol Cell Cardiol, 31:949–970. 1999.
228.
LimG, VenetucciL, EisnerD, CasadeiB. Does nitric oxide modulate cardiac ryanodine receptor function? Implications for excitation-contraction coupling. Cardiovasc Res, 77:256–264. 2008.
LipinskiM, CauthenC, Biondi-ZoccaiG, AbbateA, VrtovecB, KhanB, VetrovecG. Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure. Am J Cardiol, 104:1708–1716. 2009.
231.
LiuL, MarcocciL, WongC, ParkA, SuzukiY. Serotonin-mediated protein carbonylation in the right heart. Free Rad Biol Med, 45:847–854. 2008.
LiuY, YangX, IliodromitisE, KremastinosD, DostT, CohenM, DowneyJ. Redox signaling at reperfusion is required for protection from ischemic preconditioning but not from a direct PKC activator. Basic Res Cardiol, 103:54–59. 2008.
234.
LondonB, MichalecM, MehdiH, ZhuX, KerchnerL, SanyalS, ViswanathanP, PfahnlA, ShangL, MadhusudananM, BatyC, LaganaS, AleongR, GutmannR, AckermanM, McNamaraD, WeissR, DudleyS. Mutation in glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) decreases cardiac Na+ current and causes inherited arrhythmias. Circulation, 116:2260–2268. 2007.
235.
LopaschukG, BelkeD, GambleJ, ItoiT, SchonekessB. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta, 1213:263–276. 1994.
236.
LuikenJ, SchaapF, van NieuwenhovenF, van der VusseG, BonenA, GlatzJ. Cellular fatty acid transport in heart and skeletal muscle as facilitated by proteins. Lipids, 34:S169–S175. 1999.
MaackC, KartesT, KilterH, SchäfersH, NickenigG, BöhmM, LaufsU. Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation, 108:1567–1574. 2003.
239.
MaggioniA, FabbriG, LucciD, MarchioliR, FranzosiM, LatiniR, NicolosiG, PorcuM, CosmiF, StefanelliS, TognoniG, TavazziL. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. Eur Heart J, 30:2327–2336. 2009.
240.
MaltsevV, SabbahH, HigginsR, SilvermanN, LeschM, UndrovinasA. Novel, ultraslow inactivating sodium current in human ventricular cardiomyocytes. Circulation, 98:2545–2552. 1998.
241.
MaltsevV, SilvermanN, SabbahH, UndrovinasA. Chronic heart failure slows late sodium current in human and canine ventricular myocytes: implications for repolarization variability. Eur J Heart Fail, 9:219–227. 2007.
242.
MaltsevV, UndrovinasA. Late sodium current in failing heart: friend or foe?Prog Biophys Mol Biol, 96:421–451. 2008.
243.
MannJF, GersteinHC, PogueJ, BoschJ, YusufS. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med, 134:629–636. 2001.
244.
MarklundS. Distribution of CuZn superoxide dismutase and Mn superoxide dismutase in human tissues and extracellular fluids. Acta Physiol Scand Suppl, 492:19–23. 1980.
245.
MarksA, ReikenS, MarxS. Progression of heart failure: is protein kinase a hyperphosphorylation of the ryanodine receptor a contributing factor?Circulation, 105:272–275. 2002.
246.
MartynK, FrederickL, von LoehneysenK, DinauerM, KnausU. Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases. Cell Signal, 18:69–82. 2006.
247.
MassionP, FeronO, DessyC, BalligandJ. Nitric oxide and cardiac function: ten years after, and continuing. Circ Res, 93:388–398. 2003.
248.
MatsushimaS, IdeT, YamatoM, MatsusakaH, HattoriF, IkeuchiM, KubotaT, SunagawaK, HasegawaY, KuriharaT, OikawaS, KinugawaS, TsutsuiH. Overexpression of mitochondrial peroxiredoxin-3 prevents left ventricular remodeling and failure after myocardial infarction in mice. Circulation, 113:1779–1786. 2006.
249.
MayerB, HemmensB. Biosynthesis and action of nitric oxide in mammalian cells. Trends Biochem Sci, 22:477–481. 1997.
250.
MayersR, LeightonB, KilgourE. PDH kinase inhibitors: a novel therapy for Type II diabetes?Biochem Soc Trans, 33:367–370. 2005.
251.
McIlwainC, TownsendD, TewK. Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene, 25:1639–1648. 2006.
252.
McNallyJ, DavisM, GiddensD, SahaA, HwangJ, DikalovS, JoH, HarrisonD. Role of xanthine oxidoreductase and NAD(P)H oxidase in endothelial superoxide production in response to oscillatory shear stress. Am J Physiol Heart Circ Physiol, 285:H2290–H2297. 2003.
253.
McWhinneyC, HuntR, ConradK, DostalD, BakerK. The type I angiotensin II receptor couples to Stat1 and Stat3 activation through Jak2 kinase in neonatal rat cardiac myocytes. J Mol Cell Cardiol, 29:2513–2524. 1997.
254.
MeierJ. The contribution of incretin hormones to the pathogenesis of type 2 diabetes. Best Pract Res Clin Endocrinol Metab, 23:433–441. 2009.
255.
Mekontso-DessapA, BrouriF, PascalO, LechatP, HanounN, LanfumeyL, SeifI, Benhaiem-SigauxN, KirschM, HamonM, AdnotS, EddahibiS. Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice. Circulation, 113:81–89. 2006.
256.
MellorK, RitchieR, DelbridgeL. Reactive oxygen species and insulin resistant cardiomyopathy. Clin Exp Pharmacol Physiol, 37:222–228. 2009.
257.
MettauerB, ZollJ, GarnierA, Ventura-ClapierR. Heart failure: a model of cardiac and skeletal muscle energetic failure. Pflugers Arch, 452:653–666. 2006.
258.
Mialet-PerezJ, BianchiP, KunduzovaO, PariniA. New insights on receptor-dependent and monoamine oxidase-dependent effects of serotonin in the heart. J Neural Transm, 114:823–827. 2007.
259.
MihmMJ, CoyleCM, SchanbacherBL, WeinsteinDM, BauerJA. Peroxynitrite induced nitration and inactivation of myofibrillar creatine kinase in experimental heart failure. Cardiovasc Res, 49:798–807. 2001.
ModestiP, VanniS, BertolozziI, CecioniI, LumachiC, PernaA, BoddiM, GensiniG. Different growth factor activation in the right and left ventricles in experimental volume overload. Hypertension, 43:101–108. 2004.
262.
MoensA, KassD. Therapeutic potential of tetrahydrobiopterin for treating vascular and cardiac disease. J Cardiovasc Pharmacol, 50:238–246. 2007.
263.
MollnauH, WendtM, SzöcsK, LassègueB, SchulzE, OelzeM, LiH, BodenschatzM, AugustM, KleschyovAL, TsilimingasN, WalterU, FörstermannU, MeinertzT, GriendlingK, MünzelT. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res, 90:E58–E65. 2002.
264.
MolyneuxSL, ChristopherM, FlorkowskiMD, GeorgePM, PilbrowAP, FramptonCM, LeverM, RichardsAM. Coenzyme Q10An independent predictor of mortality in chronic heart failure. J Am Coll Cardiol, 52:1435–1441. 2008.
265.
MoniotteS, KobzikL, FeronO, TrochuJ, GauthierC, BalligandJ. Upregulation of beta(3)-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium. Circulation, 103:1649–1655. 2001.
266.
MungrueIN, StewartDJ, HusainM. The Janus faces of iNOS. Circ Res, 93:e74. 2003.
267.
MünzelT, KurzS, RajagopalanS, ThoenesM, BerringtonWR, ThompsonJA, FreemanBA, HarrisonDG. Hydralazine prevents nitroglycerintolerance by inhibiting activation of a membrane-bound NADH oxidase: a new action for an old drug. J Clin Invest, 98:1465–1470. 1996.
268.
MurphyR, DutkaT, LambG. Hydroxyl radical and glutathione interactions alter calcium sensitivity and maximum force of the contractile apparatus in rat skeletal muscle fibres. J Physiol, 586:2203–2216. 2008.
269.
MurrayA, ColeM, LygateC, CarrC, StuckeyD, LittleS, NeubauerS, ClarkeK. Increased mitochondrial uncoupling proteins, respiratory uncoupling and decreased efficiency in the chronically infarcted rat heart. J Mol Cell Cardiol, 44:694–700. 2008.
270.
MurryCE, JenningsRB, ReimerKA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation, 74:1124–1136. 1986.
NakamuraK, FushimiK, KouchiH, MiharaK, MiyazakiM, OheT, NambaM. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and Ang-II. Circulation, 98:794–799. 1998.
273.
NakamuraS, TakamuraT, Matsuzawa-NagataN, TakayamaH, MisuH, NodaH, NabemotoS, KuritaS, OtaT, AndoH, MiyamotoK, KanekoS. Palmitate induces insulin resistance in H4IIEC3 hepatocytes through reactive oxygen species produced by mitochondria. J Biol Chem, 284:14809–14818. 2009.
274.
NassR, AibaT, TomaselliG, AkarF. Mechanisms of disease: ion channel remodeling in the failing ventricle. Nat Clin Pract Cardiovasc Med, 5:196–207. 2008.
275.
NauckM, DuranS, KimD, JohnsD, NorthrupJ, FestaA, BrodowsR, TrautmannM. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia, 50:259–267. 2007.
276.
NauckM, WollschlägerD, WernerJ, HolstJ, OrskovC, CreutzfeldtW, WillmsB. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7–36 amide]) in patients with NIDDM. Diabetologia, 39:1546–1553. 1996.
277.
NaumovaA, ChackoV, OuwerkerkR, StullL, MarbanE, WeissR. Xanthine oxidase inhibitors improve energetics and function after infarction in failing mouse hearts. Am J Physiol Heart Circ Physiol, 290:H837–H843. 2006.
278.
NedianiC, BorchiE, GiordanoC, BaruzzoS, PonzianiV, SebastianiM, NassiP, MugelliA, d'AmatiG, CerbaiE. NADPH oxidase-dependent redox signaling in human heart failure: relationship between the left and right ventricle. J Mol Cell Cardiol, 42:826–834. 2007.
279.
NicolsonG. Metabolic syndrome and mitochondrial function:molecular replacement and antioxidant supplements to preventmembrane peroxidation and restore mitochondrial function. J Cell Biochem, 100:1352–1369. 2007.
280.
NiliusB, VianaF, DroogmansG. Ionic channels in vascular endothelium. Ann Rev Physiol, 59:145–170. 1997.
281.
Noyan-AshrafM, MomenM, BanK, SadiA, ZhouY, RiaziA, BaggioL, HenkelmanR, HusainM, DruckerD. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes, 58:975–983. 2009.
282.
O'NeillB, KimJ, WendeA, TheobaldH, TuineiJ, BuchananJ, GuoA, ZahaV, DavisD, SchellJ, BoudinaS, WaymentB, LitwinS, ShioiT, IzumoS, BirnbaumM, AbelE. A conserved role for phosphatidylinositol 3-kinase but not Akt signaling in mitochondrial adaptations that accompany physiological cardiac hypertrophy. Cell Metab, 6:294–306. 2007.
OeseburgH, de BoerRA, BuikemaH, van der HarstP, van GilstWH, SilljéHH. Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler Thromb Vasc Biol, 30:1407–1414. 2010.
285.
OjukaEO. Role of calcium and AMP kinase in the regulation of mitochondrial biogenesis and GLUT4 levels in muscle. Proc Nutr Soc, 63:275–278. 2004.
286.
OpieL, KnuutiJ. The adrenergic-fatty acid load in heart failure. J Am Coll Cardiol, 54:1637–1646. 2009.
287.
OtaniH. The role of nitric oxide in myocardial repair and remodeling. Antioxid Redox Signal, 11:1913–1928. 2009.
288.
OuditG, KassiriZ, ZhouJ, LiuQ, LiuP, BackxP, DawoodF, CrackowerM, ScholeyJ, PenningerJ. Loss of PTEN attenuates the development of pathological hypertrophy and heart failure in response to biomechanical stress. Cardiovasc Res, 78:505–514. 2008.
289.
OuedraogoR, WuX, XuSQ, FuchselL, MotoshimaH, MahadevK, HoughK, ScaliaR, GoldsteinBJ. Adiponectin suppression of high-glucose-induced reactive oxygen species in vascular endothelial cells: evidence for involvement of a cAMP signaling pathway. Diabetes, 55:1840–1846. 2006.
290.
PacherP, BeckmanJS, LiaudetL. Nitric oxide and peroxynitrite in health and disease. Physiol Rev, 87:315–424. 2007.
291.
PacherP, SchulzR, LiaudetL, SzabóC. Nitrosative stress and pharmacological modulation of heart failure. Trends Pharmacol Sci, 26:302–310. 2005.
292.
PaganoP, ClarkJ, Cifuentes-PaganoM, ClarkS, CallisG, QuinnM. Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. Proc Natl Acad Sci USA, 94:14483–14488. 1997.
293.
PalaL, PezzatiniA, DicembriniI, CianiS, GelminiS, VannelliBG, CresciB, MannucciE, RotellaCM. Different modulation of dipeptidyl peptidase-4 activity between microvascular and macrovascular human endothelial cells. Acta Diabetol, 2010[Epub ahead of print].
PaternostroG, PaganoD, Gnecchi-RusconeT, BonserR, CamiciP. Insulin resistance in patients with cardiac hypertrophy. Cardiovasc Res, 42:246–253. 1999.
296.
Pérez-GarcíaM, López-LópezJ, GonzálezC. Kvbeta1.2 subunit coexpression in HEK293 cells confers O2 sensitivity to kv4.2 but not to Shaker channels. J Gen Physiol, 113:897–907. 1999.
297.
PerryT, LahiriD, SambamurtiK, ChenD, MattsonM, EganJ, GreigN. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res, 72:603–612. 2003.
298.
PetersenK, ShulmanG. Etiology of insulin resistance. Am J Med, 119:10S–16S. 2006.
299.
PiacentinoV3rd, WeberC, ChenX, Weisser-ThomasJ, MarguliesK, BersD, HouserS. Cellular basis of abnormal calcium transients of failing human ventricular myocytes. Circ Res, 92:6651–6658. 2003.
300.
PiaoL, FangY, CadeteV, WietholtC, UrbonieneD, TothP, MarsboomG, ZhangH, HaberI, RehmanJ, LopaschukG, ArcherS. The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle. J Mol Med, 88:47–60. 2010.
301.
PittB, RemmeW, ZannadF, NeatonJ, MartinezF, RonikerB, BittmanR, HurleyS, KleimanJ, GatlinM. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med, 348:1309–1321. 2003.
PuwanantS, HamiltonK, KlodellC, HillJ, SchofieldR, CleetonT, PaulyD, ArandaJ. Tricuspid annular motion as a predictor of severe right ventricular failure after left ventricular assist device implantation. J Heart Lung Transplant, 27:1102–1107. 2008.
304.
RadiR, TurrensJ, ChangL, BushK, CrapoJ, FreemanB. Detection of catalase in rat heart mitochondria. J Biol Chem, 266:22028–22034. 1991.
305.
RaimondiL, BanchelliG, SgromoL, PirisinoR, NerM, PariniA, CC. Hydrogen peroxide generation by monoamine oxidases in rat white adipocytes: role on cAMP production. Eur J Pharmacol, 395:177–182. 2000.
306.
RaimondiL, De PaoliP, MannucciE, LonardoG, SartianiL, BanchelliG, PirisinoR, MugelliA, CerbaiE. Restoration of cardiomyocyte functional properties by angiotensin II receptor blockade in diabetic rats. Diabetes, 53:1927–1933. 2004.
307.
RainaA, PickeringT, ShimboD. Statin use in heart failure: a cause for concern?Am Heart J, 152:39–49. 2006.
308.
RavnanSL, RavnanMC, DeedwaniaPC. Pharmacotherapy in congestive heart failure: diuretic resistance and strategies to overcome resistance in patients with congestive heart failure. Congest Heart Fail, 8:80–85. 2002.
309.
RazeghiP, YoungM, AlcornJ, MoravecC, FrazierO, TaegtmeyerH. Metabolic gene expression in fetal and failing human heart. Circulation, 104:2923–2931. 2001.
310.
ReffelmannT, KlonerRA. Ranolazine: an anti-anginal drug with further therapeutic potential. Expert Rev Cardiovasc Ther, 8:319–329. 2010.
311.
ReifA, FröhlichL, KotsonisP, FreyA, BömmelH, WinkD, PfleidererW, SchmidtH. Tetrahydrobiopterin inhibits monomerization and is consumed during catalysis in neuronal NO synthase. J Biol Chem, 274:24921–24929. 1999.
312.
ReinartzM, DingZ, FlögelU, GödeckeA, SchraderJ. Nitrosative stress leads to protein glutathiolation, increased S-nitrosation, and up-regulation of peroxiredoxins in the heart. J Biol Chem, 283:17440–17449. 2008.
313.
RheeS, YangK, KangS, WooH, ChangT. Controlled elimination of intracellular H(2)O(2): regulation of peroxiredoxin, catalase, and glutathione peroxidase via post-translational modification. Antioxid Redox Signal, 7:619–626. 2005.
314.
RiderM, BertrandL, VertommenD, MichelsP, RousseauG, HueL. 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase: head-to-head with a bifunctional enzyme that controls glycolysis. Biochem J, 381:561–579. 2004.
315.
RitchieR. Evidence for a causal role of oxidative stress in the myocardial complications of insulin resistance. Heart Lung Circ, 18:11–18. 2009.
316.
RitchieR, QuinnJ, CaoA, DrummondG, KayeD, FavaloroJ, ProiettoJ, DelbridgeL. The antioxidant tempol inhibits cardiac hypertrophy in the insulin-resistant GLUT4-deficient mouse in vivo. J Mol Cell Cardiol, 42:1119–1128. 2007.
317.
RitzelR, OrskovC, HolstJJ, NauckMA. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7–36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia, 38:720–725. 1995.
318.
RozanskiG, XuZ. Glutathione and K(+) channel remodeling in postinfarction rat heart. Am J Physiol Heart Circ Physiol, 282:H2346–H2355. 2002.
319.
RozanskiG, XuZ, ZhangK, PatelK. Altered K+ current of ventricular myocytes in rats with chronic myocardial infarction. Am J Physiol, 274:H259–H265. 1998.
320.
RozecB, GauthierC. beta3-adrenoceptors in the cardiovascular system: putative roles in human pathologies. Pharmacol Ther, 111:652–673. 2006.
321.
RuppH, ElimbanV, DhallaN. Modification of subcellular organelles in pressure-overloaded heart by etomoxir, a carnitine palmitoyltransferase 1 inhibitor. FASEB J, 6:2349–2353. 1992.
322.
RuppH, SchulzeW, VetterR. Dietary medium-chain triglycerides can prevent changes in myosin and SR due to CPT-1 inhibition by etomoxir. Am J Physiol, 269:R630–R640. 1995.
323.
RutanenJ, YaluriN, ModiS, PihlajamäkiJ, VänttinenM, ItkonenP, KainulainenS, YamamotoH, LagougeM, SinclairD, ElliottP, WestphalC, AuwerxJ, LaaksoM. SIRT1 mRNA expression may be associated with energy expenditure and insulin sensitivity. Diabetes, 59:829–835. 2010.
324.
SaavedraWF, PaolocciN, St JohnME, SkafMW, StewartGC, XieJS, HarrisonRW, ZeichnerJ, MudrickD, MarbánE, KassDA, HareJM. Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ Res, 90:297–304. 2002.
325.
SamF, KerstetterD, PimentalD, MulukutlaS, TabaeeA, BristowM, ColucciW, SawyerD. Increased reactive oxygen species production and functional alterations in antioxidant enzymes in human failing myocardium. J Card Fail, 11:473–480. 2005.
326.
SandströmJ, NilssonP, KarlssonK, MarklundS. 10-Fold increase in human plasma extracellular superoxide dismutase content caused by a mutation in heparin-binding domain. J Biol Chem, 269:19163–19166. 1994.
327.
SaraivaRM, HareJM. Nitric oxide signaling in the cardiovascular system: implications for heart failure. Curr Opin Cardiol, 21:221–228. 2006.
328.
SartianiL, De PaoliP, StillitanoF, AimondF, VassortG, MugelliA, CerbaiE. Functional remodeling in post-myocardial infarcted rats: focus on beta-adrenoceptor subtypes. J Mol Cell Cardiol, 40:258–266. 2006.
329.
SchaperJ, FroedeR, HeinS, BuckA, HashizumeH, SpeiserB, FriedlA, BleeseN. Impairment of myocardial ultrastructure and changes of the cytoskeleton in dilated cardiomyopathy. Circulation, 83:504–514. 1991.
330.
Scherrer-CrosbieM, UllrichR, BlochK, NakajimaH, NasseriB, AretzH, LindseyM, VanconA, HuangP, LeeR, ZapolW, PicardM. Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. Circulation, 104:1286–1291. 2001.
331.
SchirraJ, KatschinskiM, WeidmannC, SchäferT, WankU, ArnoldR, GökeB. Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest, 97:92–103. 1996.
332.
Schmidt-SchwedaS, HolubarschC. First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci, 99:27–35. 2000.
333.
SchrauwenP, HoeksJ, HesselinkMK. Putative function and physiological relevance of the mitochondrial uncoupling protein-3: involvement in fatty acid metabolism?Prog Lipid Res, 45:17–41. 2006.
334.
SchroderE, WaitR, BegumS, KentishJ, EatonP. Oxidant-induced activation of type I protein kinase A is mediated by RI subunit interprotein disulfide bond formation. J Biol Chem, 281:21827–21836. 2006.
SebastianiM, GiordanoC, NedianiC, TravagliniC, BorchiE, ZaniM, FecciaM, ManciniM, PetrozzaV, CossarizzaA, GalloP, TaylorR, d'AmatiG. Induction of mitochondrial biogenesis is a maladaptive mechanism in mitochondrial cardiomyopathies. J Am Coll Cardiol, 50:1362–1369. 2007.
339.
SeddonM, ShahA, CasadeiB. Cardiomyocytes as effectors of nitric oxide signalling. Cardiovasc Res, 75:315–326. 2007.
340.
ShahA, MacCarthyP. Paracrine and autocrine effects of nitric oxide on myocardial function. Pharmacol Ther, 86:49–86. 2000.
341.
ShangL, SanyalS, PfahnlA, JiaoZ, AllenJ, LiuH, DudleyS. NF-kappaB-dependent transcriptional regulation of the cardiac scn5a sodium channel by angiotensin II. Am J Physiol Cell Physiol, 294:C372–C379. 2008.
342.
SheltonM, ChockP, MieyalJ. Glutaredoxin: role in reversible protein s-glutathionylation and regulation of redox signal transduction and protein translocation. Antioxid Redox Signal, 7:348–366. 2005.
343.
ShinmuraK, BolliR, LiuSQ, TangXL, KodaniE, XuanYT, SrivastavaS, BhatnagarA. Aldose reductase is an obligatory mediator of the LatePhase of ischemic preconditioning. Circ Res, 91:240–246. 2002.
344.
ShiojiK, KishimotoC, NakamuraH, MasutaniH, YuanZ, OkaS, YodoiJ. Overexpression of thioredoxin-1 in transgenic mice attenuates adriamycin-induced cardiotoxicity. Circulation, 106:1403–1409. 2002.
345.
ShoghiK, GroplerR, SharpT, HerreroP, FettigN, SuY, MitraM, KovacsA, FinckB, WelchM. Time course of alterations in myocardial glucose utilization in the Zucker diabetic fatty rat with correlation to gene expression of glucose transporters: a small-animal PET investigation. J Nucl Med, 49:1320–1327. 2008.
346.
SilvaGB, GarvinJL. Rac1 mediates NaCl-induced superoxide generation in the thick ascending limb. Am J Physiol Renal Physiol, 298:421–425. 2010.
347.
SingelDJ, StamlerJS. Chemical physiology of blood flow regulation by red blood cells: the role of nitric oxide and S-nitrosohemoglobin. Annu Rev Physiol, 67:99–145. 2005.
348.
SivasubramaniamS, FinchC, RodriguezM, MahyN, BillettE. A comparative study of the expression of monoamine oxidase-A and -B mRNA and protein in non-CNS human tissues. Cell Tissue Res, 313:291–300. 2003.
349.
SiwikD, TzortzisJ, PimentalD, ChangD, PaganoP, SinghK, SawyerD, ColucciW. Inhibition of copper-zinc superoxide dismutase induces cell growth, hypertrophic phenotype, and apoptosis in neonatal rat cardiac myocytes in vitro. Circ Res, 85:147–153. 1999.
350.
SokosG, NikolaidisL, MankadS, ElahiD, ShannonR. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail, 12:694–699. 2006.
351.
SonneD, EngstromT, TreimanM. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9–36) amide against ischemia-reperfusion injury in rat heart. Regul Pept, 146:243–249. 2008.
352.
StanleyW, ChandlerM. Energy metabolism in the normal and failing heart: potential for therapeutic interventions. Heart Fail Rev, 7:115–130. 2002.
353.
StanleyWC, RecchiaFA, LopaschukGD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev, 85:1093–1129. 2005.
354.
StenbitA, KatzE, ChathamJ, GeenenD, FactorS, WeissR, TsaoT, MalhotraA, ChackoV, OcampoC, JelicksL, CharronM. Preservation of glucose metabolism in hypertrophic GLUT4-null hearts. Am J Physiol Heart Circ Physiol, 279:H313–H318. 2000.
355.
StiberJ, SethM, RosenbergP. Mechanosensitive channels in striated muscle and the cardiovascular system: not quite a stretch anymore. J Cardiovasc Pharmacol, 54:116–122. 2009.
SugdenMC, HolnessMJ. Therapeutic potential of the mammalian pyruvate dehydrogenase kinases in the prevention of hyperglycaemia. Curr Drug Targets Immune Endocr Metabol Disord, 2:151–165. 2002.
361.
SugdenP. Ras, Akt, and mechanotransduction in the cardiac myocyte. Circ Res, 93:1179–1192. 2003.
362.
SunE, XuH, LiuQ, ZhouJ, ZuoP, WangJ. The mechanism for the effect of selenium supplementation on immunity. Biol Trace Elem Res, 48:231–238. 1995.
363.
SunJ, MorganM, ShenR-F, SteenbergenC, MurphyE. Preconditioning results in S-nitrosylation of proteins involved in regulation of mitochondrial energetics and calcium transport. Circ Res, 101:1155–1163. 2007.
364.
SunX, WuF, DattaR, KharbandaS, KufeD. Interaction between protein kinase C delta and the c-Abl tyrosine kinase in the cellular response to oxidative stress. J Biol Chem, 275:7470–7473. 2000.
365.
SzwedH, SadowskiZ, PachockiR, Domzał-BocheńskaM, SzymczakK, SzydłowskiZ, ParadowskiA, GajosG, KałuzaG, KulonI, Wator-BrzezińskaA, ElikowskiW, KuźniakM. The antiischemic effects and tolerability of trimetazidine in coronary diabetic patients. Cardiovasc Drugs Ther, 13:217–222. 1999.
TankovaT. Current indications for metformin therapy. Rom J Intern Med, 41:215–225. 2003.
368.
TaylorAL, ZiescheS, YancyC, CarsonP, D'AgostinoR, FerdinandK, TaylorM, AdamsK, SabolinskiM, WorcelM, CohnJN. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med, 351:2049–2057. 2004.
369.
Ter KeursH, BoydenP. Calcium and arrhythmogenesis. Physiol Rev, 87:457–506. 2007.
370.
TerentyevD, GyörkeI, BelevychA, TerentyevaR, SridharA, NishijimaY, de BlancoE, KhannaS, SenC, CardounelA, CarnesC, GyörkeS. Redox modification of ryanodine receptors contributes to sarcoplasmic reticulum Ca2+ leak in chronic heart failure. Circ Res, 103:1466–1472. 2008.
371.
ThannickalV, FanburgB. Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol, 279:L1005–L1028. 2000.
372.
ThomsonMJ, FrenneauxMP, KaskiJC. Antioxidant treatment for heart failure: friend or foe?Q J Med, 102:305–310. 2009.
373.
ThrainsdottirI, MalmbergK, OlssonA, GutniakM, RydénL. Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. Diab Vasc Dis Res, 1:40–43. 2004.
TouyzR, ChenX, TabetF, YaoG, HeG, QuinnM, PaganoP, SchiffrinE. Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ Res, 90:1205–1213. 2002.
376.
TsutsuiH, KinugawaS, MatsushimaS. Mitochondrial oxidative stress and dysfunction in myocardial remodelling. Cardiovasc Res, 81:449–456. 2009.
UllrichN, FanchaouyM, GusevK, ShirokovaN, NiggliE. Hypersensitivity of excitation-contraction coupling in dystrophic cardiomyocytes. Am J Physiol Heart Circ Physiol, 297:H1992–H2003. 2009.
379.
UmarS, an der LaarseA. Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem, 333:191–201. 2010.
380.
UndrovinasA, BelardinelliL, UndrovinasN, SabbahH. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol, 17,Suppl 1:S169–S177. 2006.
381.
Ushio-FukaiM, AlexanderR, AkersM, YinQ, FujioY, WalshK, GriendlingK. Reactive oxygen species mediate the activation of Akt/protein kinase B by angiotensin II in vascular smooth muscle cells. J Biol Chem, 274:22699–22704. 1999.
382.
van BilsenM, van NieuwenhovenF, van der VusseG. Metabolic remodelling of the failing heart: beneficial or detrimental?Cardiovasc Res, 81:420–428. 2009.
383.
Van den BorneSW, DiezJ, BlankesteijnWM, VerjansJ, HofstraL, NarulaJ. Myocardial remodeling after infarction: the role of myofibroblasts. Nat Rev Cardiol, 7:30–37. 2010.
384.
van VeldhuisenD, Cohen-SolalA, BöhmM, AnkerS, BabalisD, RoughtonM, CoatsA, Poole-WilsonP, FlatherM, InvestigatorS. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (study of effects of nebivolol intervention on outcomes and rehospitalization in seniors with heart failure)J Am Coll Cardiol, 53:2150–2158. 2009.
385.
VerspohlE.J. Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-likepeptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther, 124:113–138. 2009.
386.
VickersAE. Characterization of hepatic mitochondrial injury induced by fatty acid oxidation inhibitors. Toxicol Pathol, 37:78–88. 2009.
387.
Vila PetroffM, EganJ, WangX, SollottS. Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes. Circ Res, 89:445–452. 2001.
388.
VitaleC, WajngatenM, SposatoB, GebaraO, RossiniP, FiniM, VolterraniM, RosanoGM. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J, 25:1814–1821. 2004.
389.
VoelkelN, QuaifeR, LeinwandL, BarstR, McGoonM, MeldrumD, DupuisJ, LongC, RubinL, SmartF, SuzukiY, GladwinM, DenholmE, GailD. Report of a National Heart, Lung and Blood Institute Working Group on cellular and molecular mechanisms of right heart failure. Circulation, 114:1883–1891. 2006.
390.
WallaceD. Mitochondrial diseases in man and mouse. Science, 283:1482–1488. 1999.
391.
WeissJN, KorgeP, HondaHM, PingP. Role of the mitochondrial permeability transition in myocardial disease. Circ Res, 93:292–301. 2003.
392.
WengJ, CaoY, MossN, ZhouM. Modulation of voltage-dependent Shaker family potassium channels by an aldo-keto reductase. J Biol Chem, 281:15194–15200. 2006.
393.
WenzelP, SchulzE, MünzelT. Protein kinase C-inhibiting properties of the losartan metabolite EXP3179 make the difference. Hypertension, 54:707–709. 2009.
WheelerT, FellR, HauckM. Translocation of two glucose transporters in heart: effects of rotenone, uncouplers, workload, palmitate, insulin and anoxia. Biochim Biophys Acta, 1196:191–200. 1994.
396.
WilliamsJ, ArmesillaA, MohamedT, HagartyC, McIntyreF, SchomburgS, ZakiA, OceandyD, CartwrightE, BuchM, EmersonM, NeysesL. The sarcolemmal calcium pump, a-1 syntrophin, and neuronal nitric-oxide synthase are parts of a macromolecular protein complex. J Biol Chem, 281:23341–23348. 2006.
397.
WittelesR, FowlerM. Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J Am Coll Cardiol, 51:93–102. 2008.
398.
WoldLE, DuttaK, MasonMM, RenJ, CalaSE, SchwankeML, DavidoffAJ. Impaired SERCA function contributes to cardiomyocyte dysfunction in insulin resistant rats. J Mol Cell Cardiol, 39:297–307. 2005.
399.
WolfH. Possible new therapeutic approach in diabetes mellitus by inhibition of carnitine palmitoyltransferase 1 (CPT1)Horm Metab Res Suppl, 26:62–67. 1992.
400.
WuP, PetersJ, HarrisR. Adaptive increase in pyruvate dehydrogenase kinase 4 during starvation is mediated by peroxisome proliferator-activated receptor alpha. Biochem Biophys Res Commun, 287:391–396. 2001.
401.
WuZ, PuigserverP, AnderssonU, ZhangC, AdelmantG, MoothaV, TroyA, CintiS, LowellB, ScarpullaR, SpiegelmanB. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell, 98:115–124. 1999.
402.
XiaoL, PimentelD, WangJ, SinghK, ColucciW, SawyerD. Role of reactive oxygen species and NAD(P)H oxidase in alpha(1)-adrenoceptor signaling in adult rat cardiac myocytes. Am J Physiol Cell Physiol, 282:C926–C934. 2002.
403.
XuK, HusoD, DawsonT, BredtD, BeckerL. Nitric oxide synthase in cardiac sarcoplasmic reticulum. Proc Natl Acad Sci USA, 96:657–662. 1999.
404.
XuL, EuJ, MeissnerG, StamlerJ. Activation of the cardiac calcium release channel (ryanodine receptor) by poly-S-nitrosylation. Science, 279:234–237. 1998.
405.
XuZ, PatelK, LouM, RozanskiG. Up-regulation of K(+) channels in diabetic rat ventricular myocytes by insulin and glutathione. Cardiovasc Res, 53:80–88. 2002.
406.
YamaneM, MatsudaT, ItoT, FujioY, TakahashiK, AzumaJ. Rac1 activity is required for cardiac myocyte alignment in response to mechanical stress. Biochem Biophys Res Commun, 353:1023–1027. 2007.
407.
YanJ, YoungM, CuiL, LopaschukG, LiaoR, TianR. Increased glucose uptake and oxidation in mouse hearts prevent high fatty acid oxidation but cause cardiac dysfunction in diet-induced obesity. Circulation, 119:2818–2828. 2009.
YangJ, ParkY, ZhangH, XuX, LaineGA, DellspergerKC, ZhangC. Feed-forward signaling of TNF-alpha and NF-kappa B via IKK-beta pathway contributes to insulin resistance and coronary arteriolar dysfunction in type 2 diabetic mice. Am J Physiol Heart Circ Physiol, 296:H1850–H1858. 2009.
410.
YarasN, BilginogluA, VassortG, TuranB. Restoration of diabetes-induced abnormal local Ca2+ release in cardiomyocytes by angiotensin II receptor blockade. Am J Physiol Heart Circ Physiol, 292:H912–H920. 2007.
411.
YoudimM, EdmondsonD, TiptonK. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci, 7:295–309. 2006.
412.
YoungM, LawsF, GoodwinG, TaegtmeyerH. Reactivation of peroxisome proliferatoractivated receptor alfa is associated with contractile dysfunction in hypertrophied rat heart. J Biol Chem, 276:44390–44395. 2001.
413.
Zarain-HerzbergA, RuppH, ElimbanV, DhallaN. Modification of sarcoplasmic reticulum gene expression in pressure overload cardiac hypertrophy by etomoxir. FASEB J, 10:1303–1309. 1996.
414.
ZelkoI, MarianiT, FolzR. Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structure, evolution, and expression. Free Radic Biol Med, 33:337–349. 2002.
ZhangM, DongY, XuJ, XieZ, WuY, SongP, GuzmanM, WuJ, ZouMH. Thromboxane receptor activates the AMP-activated protein kinase in vascular smooth muscle cells via hydrogen peroxide. Circ Res, 102:328–337. 2008.
417.
ZhangXQ, YamadaS, BarryWH. Ranolazine inhibits an oxidative stress-induced increase in myocyte sodium and calcium loading during simulated-demand ischemia. J Cardiovasc Pharmacol, 51:443–449. 2008.
418.
ZhangY, DingleL, HallR, CasadeiB. The role of nitric oxide and reactive oxygen species in the positive inotropic response to mechanical stretch in the mammalian myocardium. Biochim Biophys Acta, 1787:811–817. 2009.
419.
ZhouJ, YiJ, HuN, GeorgeA, MurrayK. Activation of protein kinase A modulates trafficking of the human cardiac sodium channel in xenopus oocytes. Circ Res, 87:33–38. 2000.
420.
ZinnA, FelsonS, FisherE, SchwartzbardA. Reassessing the cardiovascular risks and benefits of thiazolidinediones. Clin Cardiol, 31:397–403. 2008.
421.
ZioloM, KatohH, BersD. Positive and negative effects of nitric oxide on Ca(2+) sparks: influence of beta-adrenergic stimulation. Am J Physiol Heart Circ Physiol, 281:H2295–H2303. 2001.